NASAR

Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

Retrieved on: 
Thursday, September 14, 2023

Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced further positive and statistically significant efficacy data from the randomized controlled NASAR clinical trial, which evaluated their Bentrio nasal spray in seasonal allergic rhinitis (SAR).

Key Points: 
  • Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced further positive and statistically significant efficacy data from the randomized controlled NASAR clinical trial, which evaluated their Bentrio nasal spray in seasonal allergic rhinitis (SAR).
  • The reduction in nasal symptoms conferred by Bentrio was 2.4 times larger than with saline nasal spray and clinically relevant.
  • Additional data, which have become subsequently available from the NASAR trial, confirm and reinforce the body of evidence demonstrating Bentrio’s efficacy in SAR management.
  • Further, the read-out from the NASAR trial suggest that Bentrio helps reduce the need for relief medication (cetirizine nasal spray).

Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results

Retrieved on: 
Tuesday, September 12, 2023

Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m.

Key Points: 
  • Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m.
  • ET
    Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs, today provided a business update and reported its first half 2023 financial results.
  • Net loss for the first half of 2023 was CHF 5.4 million compared with CHF 8.2 million for the first half of 2022.
  • ET to discuss its business update and first half 2023 results.

Altamira Therapeutics Provides Business Update

Retrieved on: 
Friday, January 27, 2023

Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today provided a business update on its strategic repositioning and important business developments.

Key Points: 
  • Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today provided a business update on its strategic repositioning and important business developments.
  • Similarly, the Company is striving to sell or partner its other legacy assets – inner ear therapeutics.
  • Concurrently, Altamira is pursuing a divestiture or partnering transaction for the inner ear assets with other parties.
  • In the weeks and months ahead, we plan to update investors with news of our ongoing research findings and direction.”

Altamira Therapeutics Provides Update on Clinical Trials with Bentrio

Retrieved on: 
Tuesday, January 24, 2023

The treatment effect of 1.55 points in favor of Bentrio was statistically significant in the ANCOVA model (LSmeans; p = 0.015; 95% confidence interval -2.78 to -0.32).

Key Points: 
  • The treatment effect of 1.55 points in favor of Bentrio was statistically significant in the ANCOVA model (LSmeans; p = 0.015; 95% confidence interval -2.78 to -0.32).
  • The interim analysis further showed good tolerability and safety both for Bentrio and the comparator.
  • Participants were randomized at a 1:1 ratio to either receive Bentrio or saline spray via self-administration three times per day, or as needed.
  • “We are very excited about the strong efficacy signals observed with Bentrio at the halfway point of the NASAR seasonal allergic rhinitis trial in Australia,” commented Thomas Meyer, Altamira Therapeutics’ founder, Chairman, and CEO.

Altamira Therapeutics Provides Year-End 2022 Business Update

Retrieved on: 
Monday, December 19, 2022

Database about to be locked in acute COVID-19 trial with Bentrio; top-line data expected by early January 2023

Key Points: 
  • Database about to be locked in acute COVID-19 trial with Bentrio; top-line data expected by early January 2023
    HAMILTON, BERMUDA / December 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today provided a business update on its strategic repositioning and key business developments.
  • The process for the sale of the other legacy assets – inner ear therapeutics – to a European family office (the “Buyer”) is still ongoing.
  • Dr. Pañeda joined the Company in April 2022 as Chief Development Officer for the RNA business.
  • “We are making solid progress with our transformation into an RNA delivery technology company,” stated Thomas Meyer, Altamira Therapeutics’ founder, Chairman and CEO.

Fanttik Revolutionizes Jump Starting with the T8 MAX this Christmas

Retrieved on: 
Thursday, December 8, 2022

But with Fanttik's latest portable jump starter the Fanttik T8 MAX, you are independently covered.

Key Points: 
  • But with Fanttik's latest portable jump starter the Fanttik T8 MAX, you are independently covered.
  • Titan's Power:The T8 MAX has the most powerful and versatile engine starting ability in the market.
  • In fact, the Fanttik T8 MAX has already been recommended by industry influencers and NASAR G2G Racing Team.
  • This jolly Christmas, Fanttik brings the T8 MAX 3000 Amp and T8 1300 Amp Jump Starters to car owners to add to their merriment.

Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results

Retrieved on: 
Wednesday, November 30, 2022

We continue to make good progress with the transformation of Altamira into an RNA delivery technology company, stated Thomas Meyer, Altamira Therapeutics founder, Chairman and CEO.

Key Points: 
  • We continue to make good progress with the transformation of Altamira into an RNA delivery technology company, stated Thomas Meyer, Altamira Therapeutics founder, Chairman and CEO.
  • Total operating expenses for the first half of 2022 were CHF 7.5 million compared with CHF 6.5 million for the first half of 2021.
  • R&D expenses for the first half of 2022 were CHF 3.6 million compared with CHF 3.4 million for the first half of 2021.
  • Altamira expects its total cash need for funding operations in 2022 to be in the range of CHF 12.0 to 13.0 million.

Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira’s Bentrio under Controlled Grass Pollen Exposure

Retrieved on: 
Tuesday, November 8, 2022

The trial showed that BentrioTM (AM-301) alleviated allergic nasal symptoms during controlled exposure to grass pollen for four hours.

Key Points: 
  • The trial showed that BentrioTM (AM-301) alleviated allergic nasal symptoms during controlled exposure to grass pollen for four hours.
  • As previously announced, the Company is seeking to divest or out-license Bentrio for key markets in North America and Europe.
  • Bentrio showed a persisting protective effect over the four hours of pollen exposure, which was in line with the other tested barrier-forming nasal spray.
  • Bentrio showed significantly lower increases in the TNSS than HPMC during the first 40 minutes of pollen exposure.

Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia

Retrieved on: 
Monday, October 3, 2022

The primary endpoint will be the comparison of the reflective Total Nasal Symptom Score (rTNSS) under treatment with Bentrio against control.

Key Points: 
  • The primary endpoint will be the comparison of the reflective Total Nasal Symptom Score (rTNSS) under treatment with Bentrio against control.
  • Interim data from the trial were used in support of the 510(k) clearance of Bentrio by the US Food and Drug Administration (FDA).
  • We are pleased to have the first patient randomized into the continuation of the NASAR trial as the annual pollen season starts in Australia, commented Thomas Meyer, Altamira Therapeutics founder, Chairman and CEO.
  • For more info, visit: https://altamiratherapeutics.com/our-products/bentrio
    Altamira Therapeutics (NASDAQ:CYTO) is dedicated to developing therapeutics that address important unmet medical needs.